A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — TOPAZ-2

Lupus Erythematosus, Systemic Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Status Recruiting

Clinical Trial Summary

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: - How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), and the Patient Global Assessment - Visual Analog Scale (PGA-VAS). Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: - After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. - All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. - Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. - There will be a follow-up safety period that lasts up to 24 weeks. - In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lupus Erythematosus, Systemic

Clinical Trial Details

NCT number	NCT04961567
Study type	Interventional
Source	Biogen
Contact	US Biogen Clinical Trial Center
Phone	866-633-4636
Email	clinicaltrials@biogen.com
Status	Recruiting
Phase	Phase 3
Start date	July 16, 2021
Completion date	March 5, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Recruiting	`NCT05967520` - JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus	Phase 2
Completed	`NCT02875691` - Effect of Green Tea on Treatment of Lupus	Phase 2
Completed	`NCT02922114` - Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients	N/A
Withdrawn	`NCT01702038` - Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Completed	`NCT00065806` - Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A
Recruiting	`NCT03543839` - Trial of Belimumab in Early Lupus	Phase 4
Completed	`NCT03098823` - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE	Phase 4
Recruiting	`NCT05899907` - Efficacy and Safety of Telitacicept in Early SLE	Phase 4
Completed	`NCT04956484` - Belimumab In Early Systemic Lupus Erythematosus	Phase 4
Completed	`NCT05326841` - Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .	Phase 3
Completed	`NCT02655640` - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis	N/A
Completed	`NCT02034344` - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers	Phase 0
Terminated	`NCT00089804` - Study of LJP 394 in Lupus Patients With History of Renal Disease	Phase 3
Completed	`NCT00071487` - Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)	Phase 2
Completed	`NCT02349061` - A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus	Phase 2
Recruiting	`NCT05636670` - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.